This partnership will reimagine personalized health with genomics and raw PPG biometric data and create a comprehensive non-invasive and reliable precision therapeutics solution
BURBANK, Calif. , Sept. 7, 2022 /PRNewswire/ -- EndoCanna Health ("EndoCanna"), the industry leader in endocannabinoid system genomic testing, has chosen to partner with Biostrap USA , LLC ("Biostrap"), a digital health leader in pioneering the industry of medical-grade biosensors, data processing techniques and machine learning, to offer a personalized therapeutics solution.
"It's the raw data that really separated Biostrap from everybody else."
"By aligning DNA with biometrics, we are able to create hyper-personalization to offer better outcomes while minimizing adverse reactions," Len May , CEO and Founder of EndoCanna Health said, adding that "it's the raw data that really separated Biostrap from everybody else. Using the Biostrap wrist-worn device, we're able to verify the efficacy and the outcome of the actual protocol that's been suggested, creating a truly personalized therapeutic experience."
CBD and cannabinoid products available on the US market today are vast. According to Statista, sales of legal recreational cannabis are expected to reach an estimated $25 billion by 2025. While, sales of CBD products are expected to grow to $16 billion in value by 2026.
Each year, millions of people turn to these therapeutics for various reasons from easing chronic pain or anxiety and depression to helping with sleep and elevating overall mood. However, more often than not, the efficacy of these products remain questionable on an individual level. Thus, there's no one-size-fits-all solution.
The cannabis plant has more than 500 compounds and over 100 cannabinoids of which, CBD is one and THC is another. In addition to that, every individual has a unique endocannabinoid system, or ECS, that is made up of millions of cannabinoid receptors throughout the central and peripheral nervous systems.
How a person's body reacts to any type of CBD or cannabinoid product will depend on their ECS and genetic makeup. That's where the EndoCanna and Biostrap partnership makes a difference.
Through analyzing more than 675,000 Single Nucleotide Polymorphisms (SNPs) related to the ECS, the science team at EndoCanna has been able to uncover unique endocannabinoid genotypes to provide precision matching of cannabinoid and THC ratios and terpene profiles for an individual's health goals.
Taking it a step further, combining genomic data with Biostrap's ultra high-fidelity raw photoplethysmography, or PPG, biometric data will offer a wrist-worn, non-invasive way to measure treatment efficacy, improve outcomes and minimize risk or any adverse side effects.
After establishing an individual's endocannabinoid profile and receiving a personal protocol from a medical professional, an EndoCanna Care Counselor will monitor each client's sleep and nocturnal biometrics through a HIPAA-compliant platform to provide feedback and help interpret the data.
"This is the kind of partnership that shows how Biostrap's clinically reliable PPG data can bridge the gap between personalizing health interventions and treatments, and monitoring the efficacy of a prescribed protocol with data-driven accuracy," Sameer Sontakey , CEO and Co-Founder of Biostrap said. "Our team believes that providing a secure, reliable and cloud-based remote physiologic monitoring platform can truly help personalize and optimize the precision therapeutics experience."
About EndoCanna Health Endocanna Health is the industry leader in endocannabinoid system genomic testing and the manufacturer of genetically aligned formulations that create optimal cannabis experiences.
Endocanna is a biotechnology research company that utilizes a patent-pending process for its cannabinoid DNA variant report, EndoDecoded™, and product matching algorithm, EndoAligned™. EndoDNA™ provides two ways to submit DNA for analysis, either collected through a simple saliva swab or a direct upload of genetic data files from popular DNA testing services like Ancestry, 23andMe, Family TreeDNA, or MyHeritage DNA. Endocanna's HIPAA compliant and secure health and wellness portal, Mydna.live, provides customers with a personalized experience to access their EndoDecoded report and EndoAligned formulation suggestions for their specific genotype.
Learn more at www.endodna.com.
About Biostrap Biostrap is pioneering the industry of medical-grade biosensors, lossless data processing techniques and artificial intelligence and machine learning to provide custom digital health solutions for health care and government organizations, clinical research and telehealth and telemedicine industries. Biostrap captures clinical-grade, continuous, ultra high-fidelity raw signals for analysis in a cloud-based Pulse Engine™. Built with convenience, efficiency and security in mind, Biostrap translates complex biometric signals into customized insights, dashboards and mobile applications to meet their clients' needs. API & Bluetooth SDK Integration options available. Learn more at www.biostrap.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/endocanna-health-to-select-biostrap-to-further-personalize-and-optimize-clients-dna-matched-cannabinoid-experience-and-provide-a-clinically-reliable-remote-monitoring-service-301618995.html
Stéphane Bancel discusses the company’s latest Covid shot and prospects for using mRNA in seasonal flu vaccines and personalized treatments for cancer
Investors have lost patience with the slow-paced clinical trials of genetic therapies, and some are using the upbeat news to exit Intellia and peers.
In that spirit, let's examine two healthcare stocks that seem to have the tools to provide solid returns over the long term: Eli Lilly (NYSE: LLY) and Teladoc Health (NYSE: TDOC). Eli Lilly seems to excel in both areas. Take one of the company's most recent approvals: Mounjaro, a therapy used to control blood glucose levels in patients with type 2 diabetes.
Intellia said Friday it knocked out the gene responsible for a rare and deadly swelling disorder. But CRISPR stocks sank.
A San Francisco-based immunology company that wants to help eradicate infectious disease globally has expanded its footprint in St. Louis, opening a new $41 million office within the Cortex innovation district. It says the new facility will be critical to advancing research to treat several infectious diseases, including Covid-19.
Omeros Corp (NASDAQ: OMER) reported results from the narsoplimab arm of the I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative (QLHC). Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID Trial. The company said that in approximately half of the patients died in the narsoplimab group, and narsoplimab was not given or was prematurely stopped, with those patients dying 9 to 35 days later. Omeros adds that despite narso
J&J (JNJ) announces a new $5 billion stock buyback plan. CHMP recommends authorizing Pfizer's (PFE) Omicron BA.4 and BA.5 boosters in Europe.
By M. Marin NASDAQ:ABVC READ THE FULL ABVC RESEARCH REPORT Moving lead assets and earlier stage candidates forward … ABVC BioPharma (NASDAQ:ABVC), a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, central nervous system (CNS) and ophthalmology, provided an update in a letter to shareholders this week. With a broad pipeline of
Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for severe COVID-19. WHO continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization. The WHO conditional recommendation is mainly driven by the final results of the WHO-sponsored SOLIDARITY study, which showed a statistically significant 17% lowe
How do you fix a forgetful memory? Neurologist shares brain exercises to keep memory sharp, including reading fiction, cooking from recipes and playing games.
One standout in a gloomy stock market this week was Ventyx Biosciences (NASDAQ: VTYX). According to data compiled by S&P Global Market Intelligence, the clinical-stage biotech's shares soared more than 58% higher during the period, thanks to the approval of a drug that hasn't actually been developed by the company. The treatment in question is Bristol Myers Squibb's deucravacitinib (brand name: Sotyktu), which was approved by the U.S. Food and Drug Administration (FDA) last Friday.
Sen. Lindsey Graham has proposed legislation that would institute a national ban on abortion after 15 weeks, meeting resistsance from both sides of the aisle. Rep. Pramila Jayapal joins Katie Phang to discuss.
Two COVID-19 antibody therapies are no longer recommended by the World Health Organization (WHO), on the basis that Omicron and the variant's latest offshoots have likely rendered them obsolete. On Thursday, WHO experts said they strongly advised against the use of the two therapies in patients with COVID-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published https://www.bmj.com/content/370/bmj.m3379 in the British Medical Journal. GSK and partner Vir Biotechnology's sotrovimab - which has generated billions in sales and became one of the British drugmaker's top sellers last year - was pulled off the U.S. market by the U.S. Food and Drug Administration (FDA) in April.
Lumakras had mixed results in a closely watched clinical trial comparing the drug to docetaxel. Analysts wonder if Mirati Therapeutics' drug will do better.
Based on positive top-line data from phase III on its pentavalent meningococcal vaccine, Pfizer (PFE) intends to submit a regulatory application to the FDA seeking approval by year-end.
Here's what experts say about getting the two vaccines at once.
The Health District is now offering Moderna and Pfizer BioNTech Covid-19 bivalent booster shots for county residents 12 and older.
A surgery to remove the problem tissue went "extremely well," her doctor said.
The following two healthcare stocks look like great buys for investors seeking to collect both above-average income and increase wealth. The good news for cancer patients is that Merck's (NYSE: MRK) cancer drug called Keytruda is approved in the U.S. to treat 19 different forms of the disease. Looking out over the long term, Merck's pipeline is just as strong as its existing products.
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?